A study recently published in Cancer Communications reported that LY01008 or BOYOUNUO, a bevacizumab biosimilar developed by Shandong Boan Biotechnology Co., Ltd. (“Shandong Boan”), a subsidiary of Luye Pharma Group Ltd. (“Luye Pharma”), demonstrated comparable safety, efficacy, immunogenicity, and pharmacokinetic profiles to the reference product AVASTIN in patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). The phase 3 randomized double-blind clinical trial was the largest study comparing the biosimilar with AVASTIN in the first-line treatment of Chinese patients with NSCLC. The trial included 649 NSCLC patients that were either administered BOYOUNUO (n = 324) or AVASTIN (n = 325) in combination with paclitaxel and carboplatin for 4 to 6 cycles, followed by maintenance monotherapy with the biosimilar.
BOYOUNUO is also approved in China for three other indications, including metastatic colorectal cancer, recurrent glioblastoma and hepatocellular carcinoma.
The post Bevacizumab Biosimilar Demonstrates Positive Phase 3 Results for the Treatment of Non-Small Cell Lung Cancer appeared first on Big Molecule Watch.